Clinical Trial Update: Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Imipenem/Cilastatin-XNW4107 with Imipenem/Cilastatin/Relebactam in hospital-acquired and ventilator-associated pneumonia has completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hospital-acquired Pneumonia
• Ventilator-associated Pneumonia

Drugs mentioned

• Imipenem/Cilastatin-XNW4107
• Imipenem/Cilastatin/Relebactam (imipenem/cilastatin/relebactam)

Snippet

Sponsor: Evopoint Biosciences Inc. | Conditions: Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia | Phase 3 | Status: COMPLETED | Results posted: 2025-11-06